Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy
Sign Up to like & getrecommendations! Published in 2020 at "Pediatric Dermatology"
DOI: 10.1111/pde.14495
Abstract: Cancer remains a leading cause of morbidity and mortality among children. Targeted therapies may improve survivorship; however, unique side‐effect profiles have also emerged with these novel therapies. Changes in hair, skin, and nails—termed dermatologic adverse… read more here.
Keywords: dermatologic aes; targeted therapy; treatment; cutaneous reactions ... See more keywords
Dermatologic prophylaxis and impact on patient-reported outcomes in first-line EGFR -mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.8641
Abstract: 8641 Background: The phase 2 COCOONtrial (NCT06120140) is evaluating the impact of enhanced dermatologic management (DM) in combination with amivantamab (ami) + lazertinib (laz) on reduction of skin and nail adverse events (AEs). At the… read more here.
Keywords: dermatologic aes; advanced nsclc; egfr mutant; cocoon ... See more keywords